TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16310129

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination in ninth graders with the law
Number of subjects: 75

Group type: COMPARATOR
Intervention: Hepatitis B vaccination in twelfth graders without the law
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MMR and Td vaccination rates in both grades
Number of subjects: 75
Study: 12904517

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (conjugated equine estrogens 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day)
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study: 10863422

Group type: EXPERIMENTAL
Intervention: ChemFlex
Number of subjects: 92

Group type: COMPARATOR
Intervention: Fuji IX GP
Number of subjects: 92
Study: 8983284

Group type: EXPERIMENTAL
Intervention: Ondansetron 5 mg/m2
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Ondansetron 10 mg/m2
Number of subjects: 187

Group type: COMPARATOR
Intervention: Both treatment arms (5 mg/m2 and 10 mg/m2)
Number of subjects: 187
Study: 1751459

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of gentamicin at the end of the cataract procedure (Group G)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of gentamicin and a cellulose wick drain (Group GW)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cellulose wick drain without gentamicin (Group W)
Number of subjects: 75
Study: 7064901

Group type: EXPERIMENTAL
Intervention: Vegetarian meal with high content of ascorbic acid
Number of subjects: 187

Group type: COMPARATOR
Intervention: Meals containing meat and fish
Number of subjects: 187

Group type: COMPARATOR
Intervention: Reference dose of inorganic iron (3 mg)
Number of subjects: 187
Study: 31087065

Group type: EXPERIMENTAL
Intervention: Medication reconciliation at discharge by a clinical pharmacist, a prescription check for formal flaws, interactions and missing therapy durations.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (standard discharge process).
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Intervention group.
Number of subjects: 152
Study: 28340157

Group type: EXPERIMENTAL
Intervention: Cervical lateral glide (CLG) treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (CG) - waiting list for treatment
Number of subjects: 58
Study: 25775376

Group type: EXPERIMENTAL
Intervention: Nametag positioned on the right chest side
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nametag positioned on the left chest side
Number of subjects: 100
Study: 23677817

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (INCB018424 Phosphate)
Number of subjects: 272
Study: 21482587

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (PORT)
Number of subjects: 221
Study: 19934707

Group type: EXPERIMENTAL
Intervention: Lower-extremity musculotendinous surgery
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nonsurgical cohort (control)
Number of subjects: 75
Study: 17890993

Group type: EXPERIMENTAL
Intervention: 1-page HIPAA authorization form (HAF)
Number of subjects: 6939

Group type: COMPARATOR
Intervention: No HIPAA authorization form (No HAF)
Number of subjects: 6939
Study: 12690582

Group type: EXPERIMENTAL
Intervention: Wellness intervention program (lifestyle‐change classes for 8 weeks, followed by telephone follow‐up for 3 months)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Wellness intervention program
Number of subjects: 113
Study: 10920403

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg plus naproxen sodium 550 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sumatriptan 100 mg plus placebo
Number of subjects: 67
Study: 8959522

Group type: COMPARATOR
Intervention: Dual therapy with lansoprazole (30 mg o.d.) for 8 weeks plus clarithromycin (200 mg b.i.d.) or amoxicillin (250 mg q.i.d.) for 2 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Triple therapy with lansoprazole (30 mg o.d.) and ecabet sodium (1.0 g b.i.d.) for 8 weeks plus clarithromycin (200 mg b.i.d.) or amoxicillin (250 mg q.i.d.) for 2 weeks
Number of subjects: 55
Study: 1413183

Group type: EXPERIMENTAL
Intervention: Venoruton (300 mg x 3)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3549312

Group type: EXPERIMENTAL
Intervention: Metoprolol (100-200 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30208960

Group type: EXPERIMENTAL
Intervention: SAM® Medical Junctional Tourniquet (SJT)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Junctional Emergency Treatment Tool (JETT)
Number of subjects: 227

Group type: COMPARATOR
Intervention: JETT
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: SJT
Number of subjects: 227
Study: 26671007

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT), 24 IU
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 25270192

Group type: EXPERIMENTAL
Intervention: PA-PALs with +1.5 D addition
Number of subjects: 197

Group type: COMPARATOR
Intervention: Single vision lenses (SVLs)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: PA-PALs with +1.0 D addition
Number of subjects: 197
Study: 22500855

Group type: EXPERIMENTAL
Intervention: Transmesocolic laparoscopic pyeloplasty (TM)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Colon-reflecting laparoscopic pyeloplasty (CR)
Number of subjects: 64
Study: 20592724

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 17572521

Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray (EC)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Topical anesthetic Ametop (TA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No analgesia (NO)
Number of subjects: 55
Study: 15661445

Group type: EXPERIMENTAL
Intervention: Intravenous dextromethorphan (DM) 0.5 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 24
Study: 12142863

Group type: EXPERIMENTAL
Intervention: Adderall (standard release)
Number of subjects: 6
Study: 10567867

Group type: EXPERIMENTAL
Intervention: 50 mg of recombinant tissue plasminogen activator (rtPA) and intravenous heparinization (n = 23)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: early-phase hemodilution therapy (n = 22)
Number of subjects: 58

Group type: COMPARATOR
Intervention: late-phase hemodilution therapy (n = 13)
Number of subjects: 58
Study: 8724107

Group type: EXPERIMENTAL
Intervention: Lp(a) ≥ 20 mg/dl
Number of subjects: 369

Group type: COMPARATOR
Intervention: Lp(a) < 20 mg/dl
Number of subjects: 369
Study: 2035283

Group type: EXPERIMENTAL
Intervention: 10.5 g fish oil daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5.25 g fish oil daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6786855

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (50 mg Biogastron duodenal three times daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 31565784

Group type: EXPERIMENTAL
Intervention: Animated storyline training materials
Number of subjects: 300

Group type: COMPARATOR
Intervention: Plain text training materials
Number of subjects: 300
Study: 31621546

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 28143413

Group type: EXPERIMENTAL
Intervention: EMPOWER brochure intervention
Number of subjects: 303
Study: 24913197

Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg/d
Number of subjects: 370

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d
Number of subjects: 370
Study: 24887922

Group type: EXPERIMENTAL
Intervention: Intercostal muscle flap and intracostal sutures in the study group (n=23)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional closure with pericostal sutures in the conventional group (n=25)
Number of subjects: 48
Study: 22075648

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system (OROS) methylphenidate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19433778

Group type: EXPERIMENTAL
Intervention: ramipril (5 mg/d) at bedtime
Number of subjects: 115

Group type: COMPARATOR
Intervention: ramipril (5 mg/d) on awakening
Number of subjects: 115
Study: 17766632

Group type: EXPERIMENTAL
Intervention: Educational intervention (1-day educational programme)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no intervention, n = 24)
Number of subjects: 81
Study: 15086937

Group type: EXPERIMENTAL
Intervention: Individual psychotherapy (12-week course)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Group psychotherapy (12-week course)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 89
Study: 11222463

Group type: EXPERIMENTAL
Intervention: Etanercept 5 mg/m2
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Etanercept 12 mg/m2
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 9587009

Group type: EXPERIMENTAL
Intervention: LAM intervention
Number of subjects: 698
Study: 7912097

Group type: EXPERIMENTAL
Intervention: Zidovudine (1000 mg daily in two divided doses)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 2680274

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce calorie intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and calorie intake
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Dietary counseling to reduce sodium and increase potassium intake
Number of subjects: 841

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 841
Study: 370019

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole plus trimethoprim
Number of subjects: 0
Study: 30983506

Group type: EXPERIMENTAL
Intervention: Alternate-day fasting (ADF)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 28187125

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (150 minutes per week for 26 weeks)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-aerobic stretching and toning (control group)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 76
Study: 25879905

Group type: EXPERIMENTAL
Intervention: Sit-stand workstation intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multi-component sit-stand workstation intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual desk use (control)
Number of subjects: 30
Study: 23949032

Group type: EXPERIMENTAL
Intervention: EMG Biofeedback (EMG BF), Traditional Rehabilitation and Gait Training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional Rehabilitation and Gait Training
Number of subjects: 30
Study: 22099891

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen combined with 1000 mg acetaminophen
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 71
Study: 19662384

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citalopram (40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (prior to escitalopram)
Number of subjects: 0
Study: 17893578

Group type: EXPERIMENTAL
Intervention: S(+)-ketamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 24
Study: 16764041

Group type: EXPERIMENTAL
Intervention: Isotonic magnesium sulphate as a vehicle for nebulized salbutamol
Number of subjects: 219

Group type: COMPARATOR
Intervention: Saline as a vehicle for nebulized salbutamol
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Isotonic magnesium sulphate in severe asthma patients
Number of subjects: 219
Study: 12701547

Group type: EXPERIMENTAL
Intervention: Behavioral interventions (41 cohorts, 8,885 subjects)
Number of subjects: 18922

Group type: EXPERIMENTAL
Intervention: Educational interventions (22 cohorts, 6,392 subjects)
Number of subjects: 18922

Group type: EXPERIMENTAL
Intervention: Combined interventions (32 cohorts, 3,645 subjects)
Number of subjects: 18922

Group type: EXPERIMENTAL
Intervention: Overall adherence increase
Number of subjects: 18922
Study: 10618930

Group type: EXPERIMENTAL
Intervention: 0.1 MAC of sevoflurane
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sustained hypercapnia
Number of subjects: 10
Study: 7496445

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 10 micrograms
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 20 micrograms
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) 30 micrograms
Number of subjects: 283
Study: 1780425

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7019840

Group type: EXPERIMENTAL
Intervention: Pancuronium bromide (administered for 12 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no pancuronium bromide, administered for 12 hours)
Number of subjects: 10
Study: 29679106

Group type: EXPERIMENTAL
Intervention: 6-week social support program
Number of subjects: 120

Group type: COMPARATOR
Intervention: Single mental health awareness session
Number of subjects: 120
Study: 27221398

Group type: EXPERIMENTAL
Intervention: Perampanel (up to 12 mg/day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 133
Study: 23976778

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham-device
Number of subjects: 23
Study: 22704741

Group type: EXPERIMENTAL
Intervention: PDA+feedback (FB)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PDA
Number of subjects: 210

Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: All groups (adherence comparison)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PDA and PDA+FB groups
Number of subjects: 210

Group type: COMPARATOR
Intervention: Combined PDA groups vs. paper diary group
Number of subjects: 210
Study: 19936588

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh (Nazca R, Promedon, Cordoba, Argentina)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sacrospinous ligament fixation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh
Number of subjects: 32
Study: 18318706

Group type: EXPERIMENTAL
Intervention: Teeth positioner (group I)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hawley's appliance (group II)
Number of subjects: 16
Study: 15922309

Group type: EXPERIMENTAL
Intervention: Bipolar disorder patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 32
Study: 11829455

Group type: EXPERIMENTAL
Intervention: Ile38 variant of hBD-1
Number of subjects: 273

Group type: COMPARATOR
Intervention: Healthy individuals without Ile38 variant
Number of subjects: 273
Study: 10367725

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (300 mg x kg(‐1) body mass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study: 7731149

Group type: EXPERIMENTAL
Intervention: Hypocapnic hypobicarbonatemic hyperventilation at 18 or 36 liter/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recovery post-hyperventilation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-adrenoreceptor blockade (timolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-adrenoreceptor blockade (phentolamine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isocapnic and isobicarbonatemic hypocapnic hyperventilation
Number of subjects: 0
Study: 2200896

Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg.kg‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Thiamylal 4 mg.kg‐1
Number of subjects: 12
Study: 7243973

Group type: EXPERIMENTAL
Intervention: Lower eyelid incision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orbital rim incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conjunctival incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subciliary incision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral canthotomy
Number of subjects: 0
Study: 30661058

Group type: EXPERIMENTAL
Intervention: Peer-based education (PE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine education (Control)
Number of subjects: 60
Study: 29045769

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Active drugs (olanzapine, quetiapine, risperidone)
Number of subjects: 371
Study: 26464455

Group type: EXPERIMENTAL
Intervention: Suvorexant (40 mg) with alcohol (0.7 g/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Suvorexant (40 mg) alone
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg) alone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 23261493

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200mg NAC twice daily)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 21876071

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/d
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Telmisartan 160 mg/d
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 18611293

Group type: EXPERIMENTAL
Intervention: Medication augmentation
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Medication switch
Number of subjects: 1286
Study: 17156300

Group type: EXPERIMENTAL
Intervention: Active eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 0
Study: 14588176

Group type: EXPERIMENTAL
Intervention: Diet 2 (pulses and egg-rich diet)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Diet 1 (vegetables and milk-rich diet)
Number of subjects: 61
Study: 10764366

Group type: EXPERIMENTAL
Intervention: Nurse Practitioner care
Number of subjects: 1368

Group type: COMPARATOR
Intervention: General Practitioner care
Number of subjects: 1368
Study: 8623731

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829
Study: 1618258

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6375889

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg qid)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Captopril (25 mg qid)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg qid) + Captopril (25 mg qid)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study: 31373563

Group type: EXPERIMENTAL
Intervention: Telephone counseling as needed for 12 weeks post-surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Regular outpatient follow-up care only for 12 weeks post-surgery
Number of subjects: 70
Study: 28013557

Group type: EXPERIMENTAL
Intervention: Traffic light nutritional labeling system awareness and comprehension among indigenous women
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Traffic light nutritional labeling system awareness and comprehension among mestiza women
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Understanding of nutrition labels
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Use of nutrition labels for food choices among mestiza women
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Use of nutrition labels for food choices among indigenous women
Number of subjects: 394
Study: 25491500

Group type: EXPERIMENTAL
Intervention: School meals rich in fish, vegetables and fibre
Number of subjects: 797

Group type: COMPARATOR
Intervention: Usual packed lunch (control)
Number of subjects: 797
Study: 24064970

Group type: EXPERIMENTAL
Intervention: Cisplatin-radiotherapy with erlotinib
Number of subjects: 204
Study: 21968871

Group type: EXPERIMENTAL
Intervention: Active product (Souvenaid)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 319
Study: 19295325

Group type: EXPERIMENTAL
Intervention: ezetimibe (10 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 16713921

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (90 g total, infused over 3 consecutive days, repeated after 3 months)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 15492308

Group type: EXPERIMENTAL
Intervention: NHA indices in symptomatic patients
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: NHA indices in APC patients
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: NHA indices in TCPC patients
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CANA indices
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CANA indices post-surgery
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: NHA and CANA correlation
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: NHA and CANA indices by age and morphology
Number of subjects: 97
Study: 11350409

Group type: EXPERIMENTAL
Intervention: Endothelin-1 mRNA in stenotic specimens
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Endothelin-1/CD31 ratio
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adrenomedullin gene expression in obstructed junctions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adrenomedullin mRNA standardized to GAPDH
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adrenomedullin mRNA standardized to CD31
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adrenomedullin mRNA standardized to smooth muscle alpha-actin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alpha-actin mRNA in stenotic tissues
Number of subjects: 20